Search Results - "Kirova, Bistra"

Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): a multi-dose, open-label, randomised, phase 2 trial by Oliveira, Mafalda, Pominchuk, Denys, Nowecki, Zbigniew, Hamilton, Erika, Kulyaba, Yaroslav, Andabekov, Timur, Hotko, Yevhen, Melkadze, Tamar, Nemsadze, Gia, Neven, Patrick, Vladimirov, Vladimir, Zamagni, Claudio, Denys, Hannelore, Forget, Frédéric, Horvath, Zsolt, Nesterova, Alfiya, Ajimi, Maxine, Kirova, Bistra, Klinowska, Teresa, Lindemann, Justin P O, Lissa, Delphine, Mathewson, Alastair, Morrow, Christopher J, Traugottova, Zuzana, van Zyl, Ruaan, Arkania, Ekaterine

“…Resistance to endocrine therapies in hormone receptor-positive breast cancer is challenging. We aimed to assess the next-generation oral selective oestrogen…”
Get full text

Abstract PS11-05: Updated data from SERENA-1: A Phase 1 dose escalation and expansion study of the next generation oral SERD AZD9833 as a monotherapy and in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer by Baird, Richard, Oliveira, Mafalda, Gil, Eva Maria Ciruelos, Patel, Manish R, Bermejo de las Heras, Begoña, Ruiz-Borrego, Manuel, García-Corbacho, Javier, Armstrong, Anne, Banerji, Udai, Twelves, Chris, Boni, Valentina, Incorvati, Jason, Kabos, Peter, Cohen, Adam L, de Paula, Bruno, Rodríguez, Marta Capelán, Wang, Judy S, Hernando, Christina, Gonzalez, Alejandro Falcón, Ruiz, Ivan Victoria, Lai-Kwon, Julia, Afghani, Anosheh, Vaklavas, Christos, Brier, Tim, Fox, Steven, Kirova, Bistra, Klinowska, Teresa, Leach, Chris, Lindemann, Justin PO, Mather, Richard, Maudsley, Rhiannon, Morrow, Christopher J, Sathiyayogan, Nitharsan, Sykes, Andy, Zhang, Li, Hamilton, Erika

“…Background: AZD9833 is an oral selective estrogen receptor (ER) antagonist and degrader (SERD) in Phase 2 clinical development for the treatment of ER+ HER2−…”
Get full text

Abstract GS3-02: GS3-02 Camizestrant, a next generation oral SERD vs fulvestrant in post-menopausal women with advanced ER-positive HER2-negative breast cancer: Results of the randomized, multi-dose Phase 2 SERENA-2 trial by Oliveira, Mafalda, Pominchuck, Denys, Nowecki, Zbigniew, Hamilton, Erika, Kulyaba, Yaroslav, Andabekov, Timur, Hotko, Yevhen, Melkadze, Tamar, Nemsadze, Gia, Neven, Patrick, Semegen, Yuriy, Vladmirov, Vladmir, Zamagni, Claudio, Denys, Hannelore, Forget, Frederic, Horvath, Zsolt, Nesterova, Alfiya, Bennett, Maxine, Kirova, Bistra, Klinowska, Teresa, Lindemann, Justin, Lissa, Delphine, Mathewson, Alastair, Morrow, Christopher, Traugottova, Zuzana, Van Zyl, Ruaan, Arkania, Ekaterine

“…Background Camizestrant (C), a next-generation oral selective estrogen receptor (ER) antagonist and degrader (ngSERD) has shown promising clinical activity in…”
Get full text

Abstract P3-07-28: SERENA-1: Updated analyses from a Phase 1 study of the next generation oral selective estrogen receptor degrader camizestrant (AZD9833) combined with abemaciclib, in women with ER-positive, HER2-negative advanced breast cancer by Turner, Nicholas, Vaklavas, Christos, Calvo, Emiliano, Garcia-Corbacho, Javier, Incorvati, Jason, Borrego, Manuel Ruiz, Twelves, Chris, Armstrong, Anne, Bermejo, Begoña, Hamilton, Erika, Oliveira, Mafalda, Ciruelos, Eva, Kabos, Peter, Patel, Manish R, Borrell, Maria, Burris, Howard, de Paula, Bruno, Falcon, Alejandro, Hernando, Cristina, Moreno, Irene, O’Brien, Ciara S., Shagisultanova, Elena, Ruiz, Ivan Victoria, Wang, Judy S., Wei, Mei, Brier, Tim, Carroll, Danielle, Ciardullo, Carmela, Gibbons, Lisa, irurzun-Arana, itziar, Jack, Tony, kirova, bistra, Klinowska, Teresa, Lindemann, Justin, Maidment, Julie, Mathewson, Alastair, Maudsley, Rhiannon, McEwen, Robert, Morrow, Christopher, Sykes, Andy, Baird, Richard D.

“…Background: SERENA-1 (NCT03616587) is a Phase 1, multi-part, open-label study of camizestrant in women with ER+/HER2− advanced breast cancer. Parts A/B and C/D…”
Get full text